TORONTO -- (MARKET WIRE) -- November 28, 2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced new clinical data from a trial of Generex Oral-lyn, the Company’s proprietary oral insulin spray product.
